UBS Initiates Coverage On ResMed with Buy Rating, Announces Price Target of $290
Portfolio Pulse from richadhand@benzinga.com
UBS analyst Saul Hadassin initiates coverage on ResMed (NYSE:RMD) with a Buy rating and announces a price target of $290.
May 22, 2023 | 2:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Saul Hadassin initiates coverage on ResMed with a Buy rating and a price target of $290.
The Buy rating and price target of $290 announced by UBS analyst Saul Hadassin for ResMed (NYSE:RMD) is likely to have a positive short-term impact on the stock price. Investors may see this as a signal of confidence in the company's future performance and potential growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100